Optimizing economic outcomes in the management of COPD

References

• AghaZSchapiraRMMakerAHCost-effectivenenss of telemedicine for the delivery of outpatient pulmonary care to a rural populationTelemed J E Health200282819112419022
   PubMed Web of Science ®Google Scholar
• AnderssonFLSvenssonKGerhardsson de VerdierMHospital use for COPD patients during the last few years of their lifeRespir Med200610014364116343887
   PubMed Web of Science ®Google Scholar
• AntoJMVermeirePVestboJEpidemiology of chronic obstructive pulmonary diseaseEur Respir J2001179829411488336
   PubMed Web of Science ®Google Scholar
• BergnerMHudsonIDConradDAThe cost and efficacy of home care for patients with chronic lung diseaseMed Care199826566793379988
   PubMed Web of Science ®Google Scholar
• BorgSEricssonAWedzichaJA computer simulation model of the natural history and economic impact of chronic obstructive pulmonary diseaseValue Health200471536715164805
   PubMed Web of Science ®Google Scholar
• BrittonMThe burden of COPD in the U.K.: results from the confronting COPD surveyRespir Med200397Suppl CS71912647945
   PubMed Web of Science ®Google Scholar
• BurgePSCalverlyPMJonesPWRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ2000320129730310807619
   PubMed Web of Science ®Google Scholar
• CalverlyPMBoonsawatWCsekeZMaintenace therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J2003c2291219
   Web of Science ®Google Scholar
• CalverleyPMBurgePSSpencerSBronchodilator reversibility testing in chronic obstructive pulmonary diseaseThorax2003a586596412885978
   PubMed Web of Science ®Google Scholar
• CalverleyPMAFergusonGTAndersonJAThe TORCH (TOwards a Revolution in COPD Health) study:salmeterol/fluticasone propionate (SFC) improves survival in COPD over three yearsEur Respir J200628Suppl 5034S
   Google Scholar
• CalverleyPPauwelsRVestoJCombination salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomized controlled trialLancet2003b3614495612583942
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once daily inhaled ipratropium in chronic obstructive pulmonary diseaseEur Respir J2002192172411866001
   PubMed Web of Science ®Google Scholar
• CelliBCalverleyPMAAndersonJAThe Towards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 yearsChest2006130Suppl 4177S
   Web of Science ®Google Scholar
• CelliBRMacNeeWcommittee membersStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J2004239324615219010
   PubMed Web of Science ®Google Scholar
• Chan-YeungMAit-KhaledNWhiteNThe burden and impact of COPD in Asia and AfricaInt J Tuberc Lung Dis20048114
   Web of Science ®Google Scholar
• ChapmanKREpidemiology and costs of chronic obstructive pulmonary diseaseEur Respir J20062718820716387952
   PubMed Web of Science ®Google Scholar
• CliniEFoglioKBianchiLIn-hospital shrt-term training program for patients with chronic airway obstructionChest20011201500511713126
   PubMed Web of Science ®Google Scholar
• CottonMMBucknallCEDaggKDEarly discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trialThorax200055902611050257
   PubMed Web of Science ®Google Scholar
• CoyleDLeeKMThe problem of protocol driven costs in pharmacoeconomic analysisPharmacoeconomics1998143576310344904
   PubMed Web of Science ®Google Scholar
• D’SouzaAOSmithMJMillerLAAn appraisal of pharmacoeconomic evidence of maintenance therapy for COPDChest2006129169370816778291
   PubMed Web of Science ®Google Scholar
• DahlRGreehorstLANowakDInhaled formoterol dry powder versus ipratropium in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20011647788411549532
   PubMed Web of Science ®Google Scholar
• Dal NegroRWLong-term oxygen tele-home monitorino, the Italian perspectiveChest Companion Book20002479
   Google Scholar
• Dal NegroRBertoPTognellaSCost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD StudyMonaldi Arch Chest Dis20025717
   Google Scholar
• Dal NegroRRossiACerveriIThe burden of COPD in Italy:results from the Confronting COPD surveyRespir Med2003a97s435012647942
   PubMed Web of Science ®Google Scholar
• Dal NegroRWPomariCTognellaSSalmeterol and fluticasone 50 mcg/250 mcg bid in combination provides a better long-term control than salmeterol 50 mcg alone and placebo in COPD patients already treated with theophyllinePulm Pharm Ther2003b1691219
   Web of Science ®Google Scholar
• Dal NegroRWTognellaSTosattoRCosts of chronic obstructive pulmonary disease (COPD) in Italy: The SIRIO study (Social Impact of Respiratory Integrated Outcomes)Respir Med20081029210117881206
   PubMed Web of Science ®Google Scholar
• DetournayBPribilCFournierMThe SCPE study: health-acre consumption related to patients with chronic obstructive pulmonary disease in FranceValue Health200471687415164806
   PubMed Web of Science ®Google Scholar
• DrummondMDrummondMO’BrienBJStoddartGLCollection and analysis of dataMethods for the economic evaluation of health care programmes1997New York, NYOxford University Press96138
   Google Scholar
• DukiMIEffect of air pollution on respiratory health in Indonesia and its economic costArch Environ Health2003581354314535572
   PubMed Web of Science ®Google Scholar
• European Lung White Book. 2003. European Respiratory Society/European Lung Foundation.
   Google Scholar
• FeenstraTLvan GenugtenMIHoognveenRTThe impact of aging and smoking on the future burden of chronic obstructive pulmonary disease:a model analysis in The NetherlandsAm J Respir Crit Care Med2001164590611520721
   PubMed Web of Science ®Google Scholar
• FinkelsteinSMSpeedieSMPotthoffSHome telehealth improves clinical outcomes at lower cost for home healthcareTelemed J E Health2006121283616620167
   PubMed Web of Science ®Google Scholar
• FoglioKBianchiIAmbrosinoNIs it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled studyChest2001119169670411399693
   PubMed Web of Science ®Google Scholar
• FoglioKBianchiIBrulettiGLong-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstructionEur Respir J1999131253210836336
   PubMed Web of Science ®Google Scholar
• FriedmanMSerbyCWMenjogeSSPharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPDChest19991156354110084468
   PubMed Web of Science ®Google Scholar
• GagnonYMLevyARSpencerMDEconomic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organizationRespir Med20059915344516291076
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2004. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2004 Executive Summary. Based on April 1998 NHLBI/WHO Workshop.
   Google Scholar
• GodfredsenNSVestboJOslerMRisk of hospital admission and reduction:a Danish population studyThorax2002b5796772
   Web of Science ®Google Scholar
• GodtfredsenNSHolstCPrescottESmoking reduction, smoking cessation, and mortality:a 16-year follow-up of 19,732 men and women from the Copenhagen Center for Prospective Population StudiesAm J Epidemiol2002a156994100112446255
   PubMed Web of Science ®Google Scholar
• GOLD Guidelines2003 Date accessed: December 2, 2005. URL: http://www.goldcopd.com
   Google Scholar
• GolmohammadiKJakobsPCost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severityAm J Med20041163253114984818
   PubMed Web of Science ®Google Scholar
• GravilJHAl-RawasOACottonMMHome treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment serviceLancet1998351185359652670
   PubMed Web of Science ®Google Scholar
• GriffithsTIBurrMLCampbellIAResults at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trialLancet2000355362810665556
   PubMed Web of Science ®Google Scholar
• GriffithsTLPhillipsCJDaviesSCost-effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programmeThorax2001567798411562517
   PubMed Web of Science ®Google Scholar
• HalbertRJIsonakaSGeorgDInterpreting COPD prevalence estimates:what is the true burden of disease?Chest200312316849212740290
   PubMed Web of Science ®Google Scholar
• HalpinDMHealth economics of obstructive pulmonary diseaseProc Am Thorac Soc200632273316636090
   PubMedGoogle Scholar
• HillemanDEDewanNMaleskerMPharmacoeconomic evaluation of COPDChest200011812788511083675
   PubMed Web of Science ®Google Scholar
• IannazzoSPradelliLDal NegroRWAnalisi di costo efficacia nella terapia della BPCOFarmacoeconomia2005627787
   Google Scholar
• JacobsonLHertzmanPLofdahlCGThe economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1880 and 1991Resp Med20009424755
   PubMed Web of Science ®Google Scholar
• JonesPWQuality of life changes in COPD patients treated with salmeterolAm J Respir Crit Care Med1997155128399105068
   PubMed Web of Science ®Google Scholar
• JonesPWAgustiAGOutcomes and markers in the assessment of chronic obstructive pulmonary diseaseEur Respir J2006278223216585091
   PubMed Web of Science ®Google Scholar
• JonesJWilsonAParkerHEconomic evaluation of hospital at home versus hospital care:cost minimization analysis of data from randomised controlled trialBMJ199931915475010591720
   PubMed Web of Science ®Google Scholar
• KaplanRMRiesALFishmanAPCost effectiveness of pulmonary rehabilitationPulmonary Rehabilitation1996New York, Basel, Hong KongMarcel Dekker37998
   Google Scholar
• KinnunenTSaynajakangasOKeistinenTThe COPD-induced hospitalization burden from first admission to deathRespir Med2006 in press
   Web of Science ®Google Scholar
• LeeTASullivanSTBuistASEstimating the future economic burden of COPDATS Procedings20063A598
   Google Scholar
• LeighJPRomanoPSSchenkerMBCosts of occupational COPD and asthmaChest20021212647211796461
   PubMed Web of Science ®Google Scholar
• LopezADMurrayCCThe global burden of disease, 1990–2020Nat Med19984124139809543
   PubMed Web of Science ®Google Scholar
• MacIntyreCRRuthDAnsariZHospital in the home is cost saving for appropriately selected patients: a comparison with in-hospital careInt J Qual Health Care2002142859312201187
   PubMed Web of Science ®Google Scholar
• ManninoDMCOPD: epidemiology, prevalence, morbidity and mortality, and disease heterrogeneityChest2002121Suppl 5121s6s12010839
   PubMed Web of Science ®Google Scholar
• MasaJFSobradilloVVillasanteCCosts of chronic obstructive pulmonary disease in Spain:estimation from a population-based studyArch Bronconeumol20044072914746730
   PubMed Web of Science ®Google Scholar
• McCroryDCBrownCDGelfandSEManagement of acute exacerbations of COPD. A summary and appraisal of public evidenceChest2001119119020911296189
   PubMed Web of Science ®Google Scholar
• MichelettoCDal NegroRWDal NegroRWGoldbergAIThe additional value of telemedicineHome long-term oxygen treatment in Italy. Complicating events in patients during LTOT2005Springer10918
   Google Scholar
• MichelettoCPomariCRighettiPA two-year health economics survey on 61 subjects in telemetric LTOT: preliminary resultsEur Respir J19947Suppl 18266
   Google Scholar
• MillerRMGeorgeDHalbertRJImproving the management of chronic obstructive pulmonary diseaseJ Health Qual200527427
   Google Scholar
• MinkoffNBAnalysis of the current care model of the COPD patient:a health outcomes assessment and economic evaluationJ Manag Care Pharm200511s3715998173
   PubMedGoogle Scholar
• MiravittlesMMurioCTina GuerreroTPharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPDChest200212114495512006427
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADAlternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyLancet199734914985049167458
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood InstituteMorbidity and mortality 2004 chart book on cardiovascular, lung, and blood diseases2004 URL: http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf Accessed Sept. 13, 2004
   Google Scholar
• NishimuraSZaherCCost impact of COPD in Japan:opportunities and challenges?Respirology200494667315612957
   PubMed Web of Science ®Google Scholar
• OfmanJJBadamgaravEHenningJMDoes disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic reviewAm J Med20041171829215300966
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten von MolkenMPAlMJOne-year cost-effectiveness of tiotropium versus ipatropiumto treat chronic obstructive pulmonary diseasesEur Respir J200423241914979498
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPMGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Respir Crit Care Med200116312567611316667
   PubMedGoogle Scholar
• PauwelsRALofdhalCGLaitinenLALong term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smokingN Engl J Med199934019485310379018
   PubMed Web of Science ®Google Scholar
• PetersJEconomic burden of environmental tobacco smoke on Hong Kong families:scale and impactJ Epidemiol Community Health1998525389604042
   PubMed Web of Science ®Google Scholar
• RamseySDSullivanSDChronic obstructive pulmonary disease: is there a case for early intervention?Am J Med2004117Suppl 12310
   Google Scholar
• RavasioRDal NegroRWLucioniCValutazione economica dei costi associati al trattamento di pazienti con ossigenoterapia di lungo termine con o senza teleossimetriaFarmacoecononia2005634952
   Google Scholar
• RennardSDecramerMCalverleyPMAImpact of COPD in North America and Europe in 2000:subjects’ perspective of Confronting COPD International SurveyEur Respir J20022079980512412667
   PubMed Web of Science ®Google Scholar
• Rutten van MolkenMPFeenstraTLThe burden of asthma and chronic obstructive pulmonary disease:data from The NetherlandsPharmacoeconomics200119Suppl 21611700783
   PubMed Web of Science ®Google Scholar
• SchmierJKHalpernMTJonesMLEffects of inhaled corticosteroids on mortality and hospitalization in elderly asthma and chronic obstructive pulmonary disease patients:appraising the evidenceDrugs Aging2005227172916156676
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981571418229603117
   PubMed Web of Science ®Google Scholar
• SilvermanEKSpeizerFRRisk factors for the development of chronic obstructive pulmonary diseaseMed Clin North Am199680501228637301
   PubMed Web of Science ®Google Scholar
• SinDDGolmohammadiKJacobsPCost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severityAm J Med20041163253114984818
   PubMed Web of Science ®Google Scholar
• SkrepnekGHSkrepnekSVEpidemiology, clinical, and economic burden, and natural history of chronic obstructive pulmonary disease and asthmaAm J Manag Care200410s21938
   Web of Science ®Google Scholar
• SorianoJBKiriVAPrideNBInhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patientsAm J Respir Med20032677414720023
   PubMedGoogle Scholar
• SpencerMBriggsGrossmanRFDevelopment of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary diseasePharmacoeconomics2005236193715960557
   PubMed Web of Science ®Google Scholar
• StrasselsSASmithDHSullivanSDThe costs of treating COPD in the United StatesChest20011193445211171708
   PubMed Web of Science ®Google Scholar
• SullivanSDRamseySDLeeTAThe economic burden of COPDChest2000117Suppl 2s59
   PubMed Web of Science ®Google Scholar
• SzafranskyWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J200321748112570112
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseNew Engl J Med20003431902911136260
   PubMed Web of Science ®Google Scholar
• TinlelmanDNordykeRJIsonakaSThe impact of chronic obstructive pulmonary disease on long-term disability costsJ Manag Care Pharm200511253215667231
   PubMedGoogle Scholar
• ToevsCDLaplanRMAtkinCJThe costs and effects of behavioural programs in chronic obstructive pulmonary diseaseMed Care19842210881006439955
   PubMed Web of Science ®Google Scholar
• TynanAjLaneSJCOPD: illness severity, resource utilization and costIr Med J2005984142444515835510
   PubMedGoogle Scholar
• van den BoomGvan SchayckCPvan MollenMPActive detection of chronic obstructive pulmonary disease and asthma in general population. Results and economic consequences of the DIMCA programAm J Respir Crit Care Med1998158173089847260
   PubMed Web of Science ®Google Scholar
• VickenWVan NoordJAGreefhorstAPImproved health outcomes in patients with COPD during 1 year treatment with tiotropiumEur Respir J2002192091611871363
   PubMed Web of Science ®Google Scholar
• ViegiGScognamiglioABaldacciSEpidemiology of chronic obstructive pulmonary diseaseRespiration20016841911223724
   PubMed Web of Science ®Google Scholar
• WedzichaJAWilkinsonTImpact of chronic obstructive pulmonary disease exacerbations on patients and payersProc Am Thorac Soc200632182116636088
   PubMedGoogle Scholar
• World Health Organization ReportLife in the 21st CenturyA vision for all1998GenevaWorld Health Organization
   Google Scholar
• ZuwallackRIMahlerDAReillyDSalmeterol plus theophylline combination therapy in the treatment of COPDChest200111916617011399688
   PubMed Web of Science ®Google Scholar